Aroa Biosurgery to Release Small Tranche of Escrowed Director Shares

Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an announcement.

Aroa Biosurgery Limited has announced that 70,055 fully paid ordinary shares will be released from voluntary escrow on 31 March 2026, following a similar 70,055-share release on 31 March 2025. Together these tranches represent just 0.04% of the company’s issued share capital, indicating only a minor change to the overall free float.

The escrowed shares were originally issued on 22 August 2024 to non-executive director Darla Hutton after receiving shareholder approval at the 2024 Annual General Meeting. As the shares are already quoted on the ASX, the release primarily formalises their trading status and signals a modest increase in liquidity without materially diluting existing shareholders.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.16 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery Limited is a New Zealand-based soft tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products for complex wound healing and soft tissue reconstruction. Its products are based on the proprietary AROA ECM technology, an ovine-derived extracellular matrix biomaterial, and are primarily distributed in the United States via a direct sales force and partner TELA Bio, Inc.

Average Trading Volume: 124,010

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$200.4M

For a thorough assessment of ARX stock, go to TipRanks’ Stock Analysis page.